Artículos de revistas
A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer
Fecha
2021Registro en:
BMC Cancer (2021) 21:1030
10.1186/s12885-021-08745-0
Autor
Córdova Delgado, Miguel Angel
Bravo, María Loreto
Cumsille, Elisa
Hill, Charlotte N.
Muñoz Medel, Matías
Pinto, Mauricio P.
Retamal, Ignacio N.
Lavanderos, María
Miquel, Juan Francisco
Rodríguez Fernández, María
Institución
Resumen
Background: Fluoropyrimidine plus platinum chemotherapy remains the standard first line treatment for gastric
cancer (GC). Guidelines exist for the clinical interpretation of four DPYD genotypes related to severe fluoropyrimidine
toxicity within European populations. However, the frequency of these single nucleotide polymorphisms (SNPs) in the
Latin American population is low (< 0.7%). No guidelines have been development for platinum. Herein, we present
association between clinical factors and common SNPs in the development of grade 3–4 toxicity.
Methods: Retrospectively, 224 clinical records of GC patient were screened, of which 93 patients were incorporated
into the study. Eleven SNPs with minor allelic frequency above 5% in GSTP1, ERCC2, ERCC1, TP53, UMPS, SHMT1, MTHFR,
ABCC2 and DPYD were assessed. Association between patient clinical characteristics and toxicity was estimated using
logistic regression models and classification algorithms.